KR20250006312A - 선택적 에스트로겐 수용체 분해제의 제조 방법 - Google Patents

선택적 에스트로겐 수용체 분해제의 제조 방법 Download PDF

Info

Publication number
KR20250006312A
KR20250006312A KR1020247041076A KR20247041076A KR20250006312A KR 20250006312 A KR20250006312 A KR 20250006312A KR 1020247041076 A KR1020247041076 A KR 1020247041076A KR 20247041076 A KR20247041076 A KR 20247041076A KR 20250006312 A KR20250006312 A KR 20250006312A
Authority
KR
South Korea
Prior art keywords
compound
formula
phenyl
trifluoromethyl
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247041076A
Other languages
English (en)
Korean (ko)
Inventor
알론소 호세 아르게예스 델가도
보리스 아르놀도비치 체스키스
마이 칸 응우옌 호크
더글라스 패튼 키옐
위 루
니콜라스 앤드류 매그너스
데이비드 마이클 레믹
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20250006312A publication Critical patent/KR20250006312A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
KR1020247041076A 2022-02-01 2023-01-27 선택적 에스트로겐 수용체 분해제의 제조 방법 Pending KR20250006312A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263305520P 2022-02-01 2022-02-01
US63/305,520 2022-02-01
US202263409060P 2022-09-22 2022-09-22
US63/409,060 2022-09-22
PCT/US2023/011671 WO2023150056A1 (en) 2022-02-01 2023-01-27 Processes for the preparation of selective estrogen receptor degraders
KR1020247028876A KR102743629B1 (ko) 2022-02-01 2023-01-27 선택적 에스트로겐 수용체 분해제의 제조 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028876A Division KR102743629B1 (ko) 2022-02-01 2023-01-27 선택적 에스트로겐 수용체 분해제의 제조 방법

Publications (1)

Publication Number Publication Date
KR20250006312A true KR20250006312A (ko) 2025-01-10

Family

ID=85382684

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247041076A Pending KR20250006312A (ko) 2022-02-01 2023-01-27 선택적 에스트로겐 수용체 분해제의 제조 방법
KR1020247028876A Active KR102743629B1 (ko) 2022-02-01 2023-01-27 선택적 에스트로겐 수용체 분해제의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020247028876A Active KR102743629B1 (ko) 2022-02-01 2023-01-27 선택적 에스트로겐 수용체 분해제의 제조 방법

Country Status (15)

Country Link
US (1) US11926634B2 (https=)
EP (1) EP4472982A1 (https=)
JP (3) JP7387926B2 (https=)
KR (2) KR20250006312A (https=)
AU (2) AU2023216654B2 (https=)
CA (1) CA3243621A1 (https=)
CO (1) CO2024009411A2 (https=)
CR (1) CR20240283A (https=)
DO (1) DOP2024000150A (https=)
IL (1) IL313886A (https=)
JO (1) JOP20240169A1 (https=)
MX (1) MX2024009453A (https=)
PE (1) PE20241731A1 (https=)
TW (2) TWI863110B (https=)
WO (1) WO2023150056A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020137965A (ja) * 2019-03-01 2020-09-03 株式会社三洋物産 遊技機
US20240199629A1 (en) * 2022-02-01 2024-06-20 Eli Lilly And Company Processes for the preparation of selective estrogen receptor degraders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1709021B1 (en) 2004-01-22 2010-08-04 Eli Lilly And Company Selective estrogen receptor modulators for the treatment of vasomotor symptoms
US20080221163A1 (en) 2005-01-18 2008-09-11 Jeffrey Alan Dodge Selective Estrogen Receptor Modulators
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
CN103582637B (zh) * 2011-05-17 2015-08-12 弗·哈夫曼-拉罗切有限公司 酪氨酸激酶抑制剂
BR112015030595A2 (pt) 2013-06-19 2017-07-25 Seragon Pharmaceuticals Inc moduladores de receptor de estrogênio de azetidina e usos dos mesmos
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
MD3820874T2 (ro) 2018-07-12 2023-05-31 Lilly Co Eli Degradanți selectivi ai receptorului estrogen
TWI702219B (zh) 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
US11014915B2 (en) * 2019-07-22 2021-05-25 Sun Pharma Advanced Research Company Limited Selective estrogen receptor degrader
CN115175679A (zh) 2020-03-06 2022-10-11 奥列马制药公司 治疗雌激素受体相关疾病的方法
CN115867282B (zh) * 2020-03-26 2025-05-27 奈克斯拉制药英国有限公司 用于抗癌的5-氨基-8-(4-吡啶基)-[1,2,4]三唑并[4,3-c]嘧啶-3-酮化合物
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
TWI837605B (zh) 2021-03-09 2024-04-01 美商美國禮來大藥廠 使用serd組合給藥方案治療癌症之方法
TWI894443B (zh) 2021-03-16 2025-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑

Also Published As

Publication number Publication date
JP7387926B2 (ja) 2023-11-28
MX2024009453A (es) 2024-08-09
CA3243621A1 (en) 2023-08-10
EP4472982A1 (en) 2024-12-11
US11926634B2 (en) 2024-03-12
JP2023112696A (ja) 2023-08-14
KR102743629B1 (ko) 2024-12-17
AU2025234145A1 (en) 2025-10-02
US20230242545A1 (en) 2023-08-03
DOP2024000150A (es) 2024-08-30
AU2023216654B2 (en) 2025-09-25
TWI863110B (zh) 2024-11-21
JOP20240169A1 (ar) 2024-07-30
TW202523669A (zh) 2025-06-16
KR20240135862A (ko) 2024-09-12
CO2024009411A2 (es) 2024-07-29
JP2023162334A (ja) 2023-11-08
IL313886A (en) 2024-08-01
CR20240283A (es) 2024-09-03
WO2023150056A1 (en) 2023-08-10
JP7805336B2 (ja) 2026-01-23
TW202346300A (zh) 2023-12-01
PE20241731A1 (es) 2024-08-19
AU2023216654A1 (en) 2024-07-11
JP2025183283A (ja) 2025-12-16

Similar Documents

Publication Publication Date Title
US8431694B1 (en) Process for making thienopyrimidine compounds
JP2025183283A (ja) 選択的エストロゲン受容体分解剤の調製のためのプロセス
EP3898581B1 (en) Substituted heterocycle fused gamma-carbolines synthesis
CN110041333B (zh) 溴结构域抑制剂化合物及其用途
CN108699063A (zh) 一种芦可替尼的合成工艺
JP2022513934A (ja) 置換複素環縮合γ－カルボリンの合成
WO2009035668A1 (en) Facile assembly of fused benzofuro-heterocycles
JP7347852B2 (ja) 重水素化大環状化合物の調製方法
JP6332818B2 (ja) チカグレロルの中間体およびその製造法、およびチカグレロルの製造法
CN107548393B (zh) 适用于治疗癌症的1-(环)烷基吡啶-2-酮的三环稠合衍生物
BG64989B1 (bg) Заместено триазолопиридазиново производно фармацевтични състави, получени от него
US20240199629A1 (en) Processes for the preparation of selective estrogen receptor degraders
BR112024013443B1 (pt) Processos para a preparação de degradadores seletivos de receptores de estrogênio
CN102216274A (zh) (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
CN118647619A (zh) 选择性雌激素受体降解剂的制备方法
BR122025017409A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
BR122025017416A2 (pt) Compostos degradadores seletivos de receptores de estrogênio
TW202527939A (zh) 單一的軸向不對稱化合物之選擇性製造方法
TW201821403A (zh) 亞碸化合物及其用於製造苯並噻吩衍生物之方法
EP4588918A1 (en) Synthesis of (s)-1-(1-(3-chlorophenyl)-2-(dimethylamino)ethyl)- 4-(5-morpholino-1h-pyrrolo[2,3-b]pyridin-3-yl)pyridin-2(1h)-one
HK40037319A (en) Process for making tricyclic lactam compounds
JP2003221394A (ja) キヌクリジン誘導体の製造方法
HK1243069A1 (en) Process for making tricyclic lactam compounds

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000